Metabolism of atypical antipsychotics: involvement of cytochrome p450 enzymes and relevance for drug-drug interactions.
about
Oral paliperidone for schizophreniaMirtazapine, and mirtazapine-like compounds as possible pharmacotherapy for substance abuse disorders: evidence from the bench and the bedsideOptimization of the bacterial cytochrome P450 BM3 system for the production of human drug metabolitesProfile of paliperidone extended release: review of efficacy and safety data.Aripiprazole as adjunctive therapy for patients with major depressive disorder: overview and implications of clinical trial data.The effects of additional treatment with terguride, a partial dopamine agonist, on hyperprolactinemia induced by antipsychotics in schizophrenia patients: a preliminary studyLipid-lowering effects of tetradecylthioacetic acid in antipsychotic-exposed, female rats: challenges with long-term treatmentWithdrawal symptoms and rebound syndromes associated with switching and discontinuing atypical antipsychotics: theoretical background and practical recommendations.Pharmacogenetics of clozapine treatment response and side-effects in schizophrenia: an update.Role of aripiprazole in treatment-resistant schizophrenia.Severe potential drug-drug interactions in older adults with dementia and associated factors.Prescribing clozapine and rifampicin: clinical impact of their interaction.Effect of aripiprazole on cognitive function and hyperprolactinemia in patients with schizophrenia treated with risperidoneEvaluation of anxiolytic effects of aripiprazole and hydroxyzine as a combination in mice.A review of the safety and tolerability of aripiprazole.Psychotropic drugs and liver disease: A critical review of pharmacokinetics and liver toxicity.Pharmacogenetic considerations in the treatment of psychiatric disorders.Antipsychotic drug toxicology in children.Pharmacokinetics and metabolism update for some recent antipsychotics.Pharmacogenetic testing to predict antipsychotic-induced weight gain: a systematic review.The pharmacology and formulation of paliperidone extended release.Psychotropic drugs and their impact on the treatment of paediatric dental patients.Clinically significant drug interactions with atypical antipsychotics.Clinically relevant interactions between newer antidepressants and second-generation antipsychotics.Pharmacogenetics of second-generation antipsychotics.Assessing drug-drug interactions through therapeutic drug monitoring when administering oral second-generation antipsychotics.Hepatic Safety of Atypical Antipsychotics: Current Evidence and Future Directions.Olanzapine alleviates oxidative stress in the liver of socially isolated rats.Neurobehavioral and genotoxic parameters of antipsychotic agent aripiprazole in mice.Genetic Determinants of Clozapine-Induced Metabolic Side Effects.Effect of combination of aripiprazole with carbamazepine and fluvoxamine on liver functions in experimental animals.Effects of suberoylanilide hydroxamic acid on rat cytochrome P450 enzyme activities.QSAR models for P450 (2D6) substrate activity.Polymorphisms influencing olanzapine metabolism and adverse effects in healthy subjects.Clinical risks of St John's Wort (Hypericum perforatum) co-administration.The Differential Binding of Antipsychotic Drugs to the ABC Transporter P-Glycoprotein Predicts Cannabinoid-Antipsychotic Drug Interactions.Effects of aripiprazole and its active metabolite dehydroaripiprazole on the activities of drug efflux transporters expressed both in the intestine and at the blood-brain barrier.Mirtazapine in combination with perospirone synergistically enhances dopamine release in the rat prefrontal cortex via 5-HT1A receptor activation.The significance of sampling time in therapeutic drug monitoring of clozapine.Drug-drug interactions involving antidepressants: focus on desvenlafaxine.
P2860
Q24242948-930184CF-7436-441B-B891-19953C568EF0Q24622161-D60BB18A-F4A9-405A-BC95-E673360D81A5Q27027286-E1EB38F6-EA67-4C07-8E7F-22C5524E4874Q30730686-9793C151-6040-40E6-8499-C30986570B0DQ33799660-E46FAC87-5144-4220-9B84-76F17F0880A8Q34110039-5ECA79F1-E514-4A07-ABC0-B80090A654FEQ34506022-3404864E-45BF-4C87-B9DF-CA82CF2444F5Q34653803-20DBCE2D-040B-48C4-AA6D-9F87B17141E6Q35771833-71BAAD87-7E93-47BB-A193-5C3E7935D7BBQ36026776-52FA17B3-F11E-4BA7-A175-CE7DF54A89D5Q36605731-2207136D-CE2E-4947-943A-DA4AF056463DQ36953235-98E0185B-28A7-463B-8276-FD42E5C3EE49Q37155297-D387F405-196E-4B22-BD73-BEFCE25F8CBBQ37498065-3368BC1F-3510-4A1C-9F10-92DD96A389FEQ37510958-12889221-BBD8-4800-BFEB-8744CF6CF185Q37625519-6D798514-C655-457A-8D2F-F55B77539534Q37681573-40410B55-6B7C-4CAB-9176-FAE0E3B1AAC5Q37852719-CDB3BF75-32A0-403C-B0C5-5F31685064E9Q37863118-6E272A88-E069-436A-94F8-76EA33EBD9EDQ37917782-4C04F99A-6FA6-4A50-AF9D-9EAE55F0EAA3Q38067139-C36049D3-E25E-4081-90B7-027D34C8D4CDQ38116482-5942950F-0939-4F7F-B5C4-E1E9F4D411C4Q38156416-FFFFFC2F-F6E5-4850-89CF-273E2C9A6775Q38185057-F1EB69A8-F179-48E6-A7AD-A71B1C6117C3Q38217628-F390A40D-E28A-4CCE-BC25-17BC69D3B36CQ38734067-46680152-D786-4563-86DF-7903A1FF6A6AQ38838664-76538AE5-B011-44EC-A3F7-3DBB28F7F419Q38972189-6014A620-DEA9-455C-8345-B94CF09F6881Q39226303-4426258E-806F-4A27-821D-0CDA35682673Q40562486-0B5D6D3F-EAA4-4E55-9CE4-B0FF8B62E45DQ40921574-364257D0-8434-4232-B622-536249B5CB1AQ41650051-08AA0C8A-98CB-414E-A543-15E5BD169473Q45340619-0FD35703-DFA6-484A-90AC-6109EA2CC294Q46254583-A2A6E5F9-AF04-4D32-92CB-3F3367F51C14Q47774682-D33DC676-D17E-4CD9-A0C9-2EC0EEE0CDC1Q48273932-5DDF552A-670F-4E0A-B3F2-550552F76CEFQ48423410-0DA97130-68E8-4BEE-9C13-34B694D04152Q48884302-85CF1B0F-64F5-425D-8CF7-182D8F6B91FBQ51026132-F588435A-57C0-4DAA-951D-3E6A6BA69427Q52369980-70C5EABC-7DF4-414B-A2EC-FF16231E82FD
P2860
Metabolism of atypical antipsychotics: involvement of cytochrome p450 enzymes and relevance for drug-drug interactions.
description
2008 nî lūn-bûn
@nan
2008 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Metabolism of atypical antipsy ...... ce for drug-drug interactions.
@ast
Metabolism of atypical antipsy ...... ce for drug-drug interactions.
@en
Metabolism of atypical antipsy ...... ce for drug-drug interactions.
@nl
type
label
Metabolism of atypical antipsy ...... ce for drug-drug interactions.
@ast
Metabolism of atypical antipsy ...... ce for drug-drug interactions.
@en
Metabolism of atypical antipsy ...... ce for drug-drug interactions.
@nl
prefLabel
Metabolism of atypical antipsy ...... ce for drug-drug interactions.
@ast
Metabolism of atypical antipsy ...... ce for drug-drug interactions.
@en
Metabolism of atypical antipsy ...... ce for drug-drug interactions.
@nl
P2093
P1476
Metabolism of atypical antipsy ...... ce for drug-drug interactions.
@en
P2093
Glen Baker
Liana Urichuk
Serdar Dursun
Trevor I Prior
P304
P356
10.2174/138920008784746373
P407
P577
2008-06-01T00:00:00Z